Wu M, Chen H, Yao X
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai.
Zhonghua Wai Ke Za Zhi. 1996 Dec;34(12):707-10.
The mortality rate of patients with primary liver cancer (PLC) was 20.40 per 100,000 Chinese per year, that takes the second place among all forms of cancer. Surgical resection remains the modality of primary choice in the treatment of PLC. 2051 patients with PLC were treated by liver resection from 1960 to 1993. Of those, 94.1% were hepatocellular carcinoma (HCC) and the incidence of cirrhosis and chronic hepatitis was found in 86.5%. Small PLC (< or = 5 cm in diameter) was found in 25.1% of all cases. In the small PLC group, 176 cases were found the tumor < or = 3 cm in diameter. All 2051 patients received liver resection and 44.0% of them had local radical resection. The overall mortality rate within one month after operation was 1.1%. The overall 5-year survival rate was 36.1%. Improved surgical result was obtained in 515 patients with small PLC (< or = 5 cm in diameter). No operative death occurred in this group and the 5-year survival rate was 79.8%. Moreover, the patients with very small PLC (< or = 3 cm in diameter) prolonged their survival. The 5-year survival rate was 85.3%. Early diagnosis and early resection of PLC are one of the key points for improving the long-term results. Improvements in operative techniques play an important role in reducing post-operative complications, lowering operative mortality and obtaining better operative results. Rehepatectomy for recurrent liver cancer can improve the surgical results. 95 patients underwent rehepatectomy with a 5-year survival rate of 53.2% and 25.0% after the first and second operation respectively. One patient survived 18 years. For unresectable large tumors, two-stage resection can be used. We collected 659 cases of large unresectable tumors from 1974 to 1994. Among them, 73 cases were resected in two-stage operation. The resection rate was 11.1%, and the 5-year survival rate was 61.5%. Postoperative comprehensive treatment is also important for upregulating cellular immunological function, preventing tumor recurrence, and improving surgical results.
原发性肝癌(PLC)患者的死亡率为每年每10万中国人中有20.40人,在所有癌症类型中位居第二。手术切除仍然是PLC治疗的首选方式。1960年至1993年期间,2051例PLC患者接受了肝切除术。其中,94.1%为肝细胞癌(HCC),86.5%的患者存在肝硬化和慢性肝炎。所有病例中25.1%为小肝癌(直径≤5 cm)。在小肝癌组中,176例肿瘤直径≤3 cm。所有2051例患者均接受了肝切除术,其中44.0%进行了局部根治性切除。术后1个月内的总死亡率为1.1%。总体5年生存率为36.1%。515例小肝癌(直径≤5 cm)患者的手术效果得到改善。该组无手术死亡,5年生存率为79.8%。此外,极微小肝癌(直径≤3 cm)患者的生存期延长。5年生存率为85.3%。PLC的早期诊断和早期切除是改善长期疗效的关键要点之一。手术技术的改进在减少术后并发症、降低手术死亡率和获得更好的手术效果方面发挥着重要作用。复发性肝癌的再次肝切除术可改善手术效果。95例患者接受了再次肝切除术,第一次和第二次手术后的5年生存率分别为53.2%和25.0%。1例患者存活了18年。对于无法切除的大肿瘤,可采用二期切除。我们收集了1974年至1994年期间659例无法切除的大肿瘤病例。其中,73例进行了二期手术切除。切除率为11.1%,5年生存率为61.5%。术后综合治疗对于上调细胞免疫功能、预防肿瘤复发和改善手术效果也很重要。